Company Description
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications.
The company was founded in 2017 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Jodie Morrison |
Contact Details
Address: 830 Winter Street Waltham, Massachusetts 02451 United States | |
| Phone | 781 999 0232 |
| Website | q32bio.com |
Stock Details
| Ticker Symbol | QTTB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1661998 |
| CUSIP Number | 746964105 |
| ISIN Number | US7469641051 |
| Employer ID | 47-3468154 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jodie Pope Morrison | Chief Executive Officer and Director |
| Lee H. Kalowski M.B.A. | Chief Financial Officer and President |
| Dr. Shelia M. Violette Ph.D. | Co-founder, Chief Scientific Officer and President of Research |
| David Appugliese J.D. | Senior Vice President and Head of People |
| Maria Marzilli M.P.H. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 20, 2026 | SCHEDULE 13D/A | Filing |
| Jul 17, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 15, 2026 | 8-K | Current Report |
| Jul 15, 2026 | 424B5 | Filing |
| Jul 13, 2026 | EFFECT | Notice of Effectiveness |
| Jul 13, 2026 | 424B5 | Filing |
| Jul 13, 2026 | 8-K | Current Report |
| Jul 13, 2026 | 8-K | Current Report |
| Jul 10, 2026 | SCHEDULE 13G | Filing |
| Jul 6, 2026 | SCHEDULE 13G/A | Filing |